ClinicalTrials.gg
CompletedNCT07025109Updated Oct 22, 2026

Assessing Peer Support for Physical Activity in Women With HIV and Hypertension

An interventional study of Peer support and Exercise Prescription in HIV and Hypertension, sponsored by University of Alabama at Birmingham. Completed at 1 site in United States. Open to female participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Prevention

How we know

Updated Oct 22, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
40 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Hypertension by University of Alabama at Birmingham — 13 open to participants now, 16 under way, 1 of them phase 3. Hypertension · University of Alabama at Birmingham.

Enrollment
22nd of 38
42 · median 71
Started
2026
with 6 others
No phase
29 of 44
11 open now
Registered
37th of 44
by date

Among the 44 studies in Hypertension by University of Alabama at Birmingham, this one is the 22nd largest by enrollment of the 38 interventional ones that give a count, is one of 7 that started in 2026, is one of 29 with no phase, and was the 37th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

13 of the 44 studies in Hypertension by University of Alabama at Birmingham are open now, in 1 country. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 40 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Hypertension by University of Alabama at Birmingham, or all of them as a file.
02

Study summary

This clinical trial will assess the acceptability and feasibility of a peer-supported behavioral physical activity intervention for women living with HIV and Hypertension.

Read the detailed description

An individually randomized pilot trial (N=50) of an adapted behavioral physical activity (PA) intervention will be used to assess the feasibility and acceptability of providing exercise prescription, peer support, and home blood pressure monitoring to women ages 40+ living with HIV and Hypertension. Secondary outcomes to be assessed include systolic and diastolic blood pressure, PA time and intensity, PA self-efficacy, perceived social support, and health-related quality of life.

03

Conditions studied

  • HIV
  • Hypertension

Keywords

  • Women
  • HIV
  • Hypertension
  • Physical Activity
  • Behavioral clinical trial
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • woman living with
  • age 40 and above
  • diagnosed with HTN
  • access to a personal phone for study-related phone calls
  • willing to wear an accelerometer on their waist or hip for 7 days at beginning and end of 12-week intervention
  • able to ambulate independently
  • English speaking

Exclusion criteria

Exclusion Criteria:

  • Pregnant
  • unable to provide due to cognitive deficit, serious mental illness, or active substance use
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Peer support arm

    Women in the peer support arm will receive weekly peer contacts via phone or text message to assess progress towards study-assigned physical activity goal/prescription and to provide motivational counseling and support.

    Behavioral: Peer support · Behavioral: Exercise Prescription · Behavioral: Blood pressure self monitoring

  • Active comparator
    Control arm

    Women in the control arm will receive physical activity prescription and home blood pressure monitoring, but will not receive peer support calls.

    Behavioral: Exercise Prescription · Behavioral: Blood pressure self monitoring

Interventions

  • BehavioralPeer support

    Peer support counseling will include phone or text communication to assess goal progress, provide motivational counseling as needed, and to provide social support.

  • BehavioralExercise Prescription

    Women will be provided with an exercise prescription (Frequency, Intensity, Time, Type) which may be adjusted weekly for 6 weeks to goal of 150min/week of moderate to vigorous physical activity.

  • BehavioralBlood pressure self monitoring

    Women will receive a home blood pressure monitor and encourage to record their readings in a log.

06

What researchers measure

Primary outcomes

  1. Participant attrition

    Measure of participants who withdraw from the behavioral trial in the intervention and the control groups to determine feasibility of enrolling and retaining individuals in the trial. Approximately 15% attrition is expected in a behavioral clinical trial. Higher levels of attrition relate to lower feasibility.

    Time frame: From enrollment to end of 12 week intervention

  2. Intervention acceptability: Satisfaction

    Participant satisfaction with the intervention: Treatment Satisfaction Questionnaire adapted for behavioral treatment. The measure includes 11 items asked on a Likert-type scale from 1=Extremely Dissatisfied to 7=Extremely Satisfied, with 3 items asked on a 1-5 scale. 1 item will be removed that asks about medication side effects. Scores can range from 10 to 64. Higher scores mean higher satisfaction with the treatment/intervention.

    Time frame: Mid-point (6-week) assessment and end of intervention assessment (12-week)

  3. Intervention Acceptability: Treatment burden

    The Brief Patient Experiences with Treatment and Self Management will be used. The scale includes 32 items total. Most items use a 5-point Likert-type scale from 1=very easy to 5=very difficult. Some items use a 5-point Likert scale (agreement). And some use a Likert-type frequency/intensity measure from 1=not at all to 5=very much. Does not apply=0. Total scores range from 0 to 150. Higher scores mean higher treatment burden.

    Time frame: At 6-week (mid-point intervention) and 12-weeks (end of intervention)

Secondary outcomes

  1. Systolic and diastolic blood pressure

    Home blood pressure readings taken x3 and averaged.

    Time frame: Measured at baseline, 6-weeks (mid-point) and 12-weeks (end of intervention)

  2. Daily physical activity: Accelerometer measured

    7-day accelerometer observation of daily physical activity

    Time frame: Collected at baseline pre-randomization, and at 12-weeks (end of intervention)

  3. Self reported physical activity

    Time and intensity of physical activity via the International Physical Activity Questionnaire - Short Form (IPAQ-SF) which are then computed to a continuous score of MET (metabolic equivalents)-minutes per week. Computed as follows: Total PA METmin/week=\[(3.3\*walking minutes\*walking days)+(4.0\*moderate activity minutes\*moderate activity days)+(8.0\*vigorous activity minutes\*vigorous activity days)\]. Higher scores mean greater physical activity.

    Time frame: Collected at baseline, 6 weeks (mid-point), and 12-weeks (post-intervention)

  4. Physical Activity Self Efficacy

    Confidence to engage in regular physical activity will be measured using the Exercise Self Efficacy Scale. A total of 9 items are asked using a scale from 0=not at all confident to 10=completely confident. Scores range from 0-90. Higher scores mean higher self efficacy.

    Time frame: Collected at baseline, 6-weeks (mid-point) and 12-weeks (post-intervention)

  5. Physical activity enjoyment

    Physical activity enjoyment scale will be used. The scale has 18 items and each item is asked on a 1 to 7 scale. Scores may range from 18-126. Higher scores mean higher enjoyment and perceived positive outcomes from exercise/physical activity.

    Time frame: Collected at baseline, 6-weeks (mid-point), and 12-weeks (post-intervention)

  6. Social support for physical activity

    Social support for exercise behaviors scale will be used that includes 10 items asked on a scale from 1=none to 5=very often, there is also an option for does not apply. Scores range from 10-50. Higher scores mean more social support for physical activity.

    Time frame: Collected at baseline, 6-weeks (mid-point), and 12-weeks (post-intervention)

Other outcomes

  1. General Social Support

    Medical outcomes study social support scale will be used to assess global social support. The scale includes 19 items and the overall support index is calculated by taking the mean of all of the items resulting in a range from 1-5. Scores can be transformed to a 0-100 score by the following equation: 100\*((observed score-minimum possible score)/(maximum possible score-minimum possible score)). Higher scores mean greater social support.

    Time frame: Collected at baseline, 6-weeks (mid-point), and 12-weeks (post-intervention)

  2. Health related quality of life

    The Short Form Health Survey-12 (SF-12) will be used to assess Health related quality of life (HRQoL) which asks about physical and emotional health in the past 4 weeks using 12 items. In scoring, all items are coded to yield a total score between 0 and 100 such that higher scores mean better HRQoL.

    Time frame: Collected at baseline, 6-weeks (mid-point), and 12-weeks (post-intervention)

07

Study locations

1 site
  • Department of Family & Community Medicine; University of Alabama at Birmingham
    Birmingham, Alabama 35205, United States
08

References and documents

Individual participant data

Plan to share: No — Pilot trial; Certificate of confidentiality

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2026 to primary completion in Aug 2026, 6 months.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 6 months is below that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2025
First posted
Jun 17, 2025
StartActual
Feb 6, 2026
Primary completionActual
Aug 24, 2026
CompletionActual
Aug 24, 2026
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 22, 2026
Primary completion
Aug 31, 2026→Aug 24, 2026 (actual)
Oct 22, 2026
Study completion
Aug 31, 2026→Aug 24, 2026 (actual)
Oct 22, 2026
Enrollment
50 (estimated)→42 (actual)
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Active, not recruiting→Completed
    Primary completion Aug 31, 2026→Aug 24, 2026 (now actual)
    Study completion Aug 31, 2026→Aug 24, 2026 (now actual)
    Enrollment 50 (estimated)→42 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07025109
Responsible party
Kaylee Crockett (Assistant Professor, University of Alabama at Birmingham) — Principal investigator
First posted
Jun 17, 2025
Start date
Feb 6, 2026
Primary completion
Aug 24, 2026
Completion
Aug 24, 2026
Last update
Oct 22, 2026

Study contacts

Kaylee B Crockett, PhD
principal investigator · University of Alabama at Birmingham

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion